Exploring diversity in platinum(iv) N-heterocyclic carbene complexes: synthesis, characterization, reactivity and biological evaluation

Anti-Cancer and Radio-Sensitizing Properties of New Bimetallic (N-Heterocyclic Carbene)-Amine-Pt(II) Complexes

Bioactive NHC-transition metal complexes have shown promise as anti-cancer agents, but their potential use as radiosensitizers has been neglected so far. We disclose here a new series of bimetallic platinum(II) complexes displaying NHC-type bridging ligands, (bis-NHC)[trans-Pt(RNH₂)I₂]₂, that have been synthesized via a simple, two-step procedure. They display cytotoxicity in the micromolar range on cancerous cell lines, accumulate in cells, and bind to genomic DNA, by inducing DNA damages. Notably, these bimetallic complexes demonstrate significant radiosensitizing effects on both ovarian cells A2780 and nonsmall lung carcinoma cells H1299. Further investigations revealed that bimetallic species make irradiation-induced DNA damages more persistent by inhibiting repair mechanisms. Indeed, a higher and persistent accumulation of both γ-H2AX and 53BP1 foci post-irradiation was detected, in the presence of the NHC-Pt complexes. Overall, we provide the first in vitro evidence for the radiosensitizing properties of NHC-platinum complexes, which suggests their potential use in combined chemo-radio therapy protocols.

Impact of Hydrophobic Chains in Five-Coordinate Glucoconjugate Pt(II) Anticancer Agents

This study describes new platinum(II) cationic five-coordinate complexes (1-R,R') of the formula [PtR(NHC)(dmphen)(ethene)]CF₃SO₃ (dmphen = 2,9-dimethyl-1,10-phenanthroline), containing in their axial positions an alkyl group R (methyl or octyl) and an imidazole-based NHC-carbene ligand with a substituent R' of variable length (methyl or octyl) on one nitrogen atom. The Pt-carbene bond is stable both in DMSO and in aqueous solvents. In DMSO, a gradual substitution of dmphen and ethene is observed, with the formation of a square planar solvated species. Octanol/water partitioning studies have revealed the order of hydrophobicity of the complexes (1-Oct,Me > 1-Oct,Oct > 1-Me,Oct > 1-Me,Me). Their biological activity was investigated against two pairs of cancer and non-cancer cell lines. The tested drugs were internalized in cancer cells and able to activate the apoptotic pathway. The reactivity of 1-Me,Me with DNA and protein model systems was also studied using UV-vis absorption spectroscopy, fluorescence, and X-ray crystallography. The compound binds DNA and interacts in various ways with the model protein lysozyme. Remarkably, structural data revealed that the complex can bind lysozyme via non-covalent interactions, retaining its five-coordinate geometry.

N-Heterocyclic Carbene Platinum(IV) as Metallodrug Candidates: Synthesis and 195Pt NMR Chemical Shift Trend

A series of octahedral platinum(IV) complexes functionalized with both N-heterocyclic carbene (NHC) ligands were synthesized according to a straightforward procedure and characterized. The coordination sphere around the metal was varied, investigating the influence of the substituted NHC and the amine ligand in trans position to the NHC. The influence of those structural variations on the chemical shift of the platinum center were evaluated by ¹⁹⁵Pt NMR. This spectroscopy provided more insights on the impact of the structural changes on the electronic density at the platinum center. Investigation of the in vitro cytotoxicities of representative complexes were carried on three cancer cell lines and showed IC₅₀ values down to the low micromolar range that compare favorably with the benchmark cisplatin or their platinum(II) counterparts bearing NHC ligands.

Pt(II) versus Pt(IV) in Carbene Glycoconjugate Antitumor Agents: Minimal Structural Variations and Great Performance Changes

Octahedral Pt(IV) complexes (2Pt-R) containing a glycoconjugate carbene ligand were prepared and fully characterized. These complexes are structural analogues to the trigonal bipyramidal Pt(II) species (1Pt-R) recently described. Thus, an unprecedented direct comparison between the biological properties of Pt compounds with different oxidation states and almost indistinguishable structural features was performed. The stability profile of the novel Pt(IV) compounds in reference solvents was determined and compared to that of the analogous Pt(II) complexes. The uptake and antiproliferative activities of 2Pt-R and 1Pt-R were evaluated on the same panel of cell lines. DNA and protein binding properties were assessed using human serum albumin, the model protein hen egg white lysozyme, and double stranded DNA model systems by a variety of experimental techniques, including UV-vis absorption spectroscopy, fluorescence, circular dichroism, and electrospray ionization mass spectrometry. Although the compounds present similar structures, their in-solution stability, cellular uptake, and DNA binding properties are diverse. These differences may represent the basis of their different cytotoxicity and biological activity.

Relative stabilities of M/NHC complexes (M = Ni, Pd, Pt) against R-NHC, X-NHC and X-X couplings in M(0)/M(ii) and M(ii)/M(iv) catalytic cycles: a theoretical study

The complexes of Ni, Pd, and Pt with N-heterocyclic carbenes (NHCs) catalyze numerous organic reactions via proposed typical M⁰/M^II catalytic cycles comprising intermediates with the metal center in (0) and (II) oxidation states. In addition, M^II/M^IV catalytic cycles have been proposed for a number of reactions. The catalytic intermediates in both cycles can suffer decomposition via R-NHC coupling and the side reductive elimination of the NHC ligand and R groups (R = alkyl, aryl, etc.) to give [NHC-R]⁺ cations. In this study, the relative stabilities of (NHC)M^II(R)(X)L and (NHC)M^IV(R)(X)₃L intermediates (X = Cl, Br, I; L = NHC, pyridine) against R-NHC coupling and other decomposition pathways via reductive elimination reactions were evaluated theoretically. The study revealed that the R-NHC coupling represents the most favorable decomposition pathway for both types of intermediates (M^II and M^IV), while it is thermodynamically and kinetically more facile for the M^IV complexes. The relative effects of the metal M (Ni, Pd, Pt) and ligands L and X on the R-NHC coupling for the M^IV complexes were significantly stronger than that for the M^II complexes. In particular, for the (NHC)₂M^IV(Ph)(Br)₃ complexes, Ph-NHC coupling was facilitated dramatically from Pt (ΔG = -36.9 kcal mol^-1, ΔG^≠ = 37.5 kcal mol^-1) to Pd (ΔG = -61.5 kcal mol^-1, ΔG^≠ = 18.3 kcal mol^-1) and Ni (ΔG = -80.2 kcal mol^-1, ΔG^≠ = 4.7 kcal mol^-1). For the M^II oxidation state of the metal, the bis-NHC complexes (L = NHC) were slightly more kinetically and thermodynamically stable against R-NHC coupling than the mono-NHC complexes (L = pyridine). An inverse relation was observed for the M^IV oxidation state of the metal as the (NHC)₂M^IV(R)(X)₃ complexes were kinetically (4.3-15.9 kcal mol^-1) and thermodynamically (8.0-23.2 kcal mol^-1) significantly less stable than the (NHC)M^IV(R)(X)₃L (L = pyridine) complexes. For the Ni^IV and Pd^IV complexes, additional decomposition pathways via the reductive elimination of the NHC and X ligands to give the [NHC-X]⁺ cation (X-NHC coupling) or reductive elimination of the X-X molecule were found to be thermodynamically and kinetically probable. Overall, the obtained results demonstrate significant instability of regular Ni/NHC and Pd/NHC complexes (for example, not additionally stabilized by chelation) and high probability to initiate "NHC-free" catalysis in the reactions comprising M^IV intermediates.

Synthesis, structures and cytotoxic effects in vitro of cis- and trans-[PtIVCl4(NHC)2] complexes and their PtII precursors

Four new bis(N,N-dialkylbenzimidazol-2-ylidene)dichlorido platinum(ii) complexes 2 featuring N-alkyl substituents of increasing size (a: Me, b: Et, c: n-butyl, d: n-octyl) were synthesised and oxidised with PhICl₂ to give the corresponding [Pt^IVCl₄(N,N-dialkylbenzimidazol-2-ylidene)₂] complexes 4 as potential anticancer prodrugs. The known bis(N,N-dibenzylimidazol-2-ylidene)dichlorido platinum(ii) complex 1 was likewise oxidised to [Pt^IVCl₄(N,N-dibenzylimidazol-2-ylidene)₂] 3. In contrast, oxidation of complexes 1 and 2 with H₂O₂ or hypochlorites, or exchange of chlorido for hydroxo ligands in tetrachlorido complexes 4 failed to give isolable complexes of type [Pt^IVCl_4-n(OH)_n(NHC)₂]. In MTT assays the [Pt^IICl₂(NHC)₂]/[Pt^IVCl₄(NHC)₂] complex couples 1/3, 2c/4c, and trans-2c/trans-4c, bearing either N-benzyl or N-butyl substituents, each showed similar single-digit micromolar IC₅₀ values against at least three out of five human cancer cell lines, presumably due to an intracellular reduction of the Pt^IV complexes to their active Pt^II congeners. Unlike cisplatin, whose anticancer effect requires functional p53, each of them was active both in wildtype and in p53-negative HCT116 colon carcinoma cells. In ethidium bromide saturation assays with isolated DNA, cis-(bis-NHC)Pt^II complexes such as 1 caused morphological DNA changes more pronounced than those initiated by cisplatin, while the corresponding cis-(bis-NHC)Pt^IV complexes such as 3 interacted with DNA in a less structure-modifying way.

Synthesis and Structures of Stable PtII and PtIV Alkylidenes: Evidence for π-Bonding and Relativistic Stabilization

Isolable cationic Pt^II and Pt^IV alkylidenes, proposed intermediates in catalytic organic transformations, are reported. The bonding in these species was probed by experimental, structural, spectroscopic, electrochemical and computational methods, providing direct evidence for π-bonding, the often-theorized relativistic stabilization of these species, and the influence of oxidation state.

Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation

A new series of glucose-conjugated Pt(IV) complexes that target tumor-specific glucose transporters (GLUTs) was designed, synthesized, and evaluated for their anticancer activities. All six compounds, namely, A1-A6, exhibited increased cytotoxicity that were almost six fold higher than that of oxaliplatin to MCF-7 cells. These Pt(IV) complexes can be reduced to release Pt(II) complexes and cause the death of tumor cells. Simultaneously, the glycosylated Pt(IV) complexes (30.21-91.33 μM) showed lower cytotoxicity that normal LO2 cells compared with cisplatin (5.25 μM) and oxaliplatin (8.34 μM). The intervention of phlorizin as a GLUTs inhibitor increased the IC₅₀ value of the glycosylated Pt(IV) complexes, thereby indicating the potential GLUT transportability. The introduction of glucose moiety to Pt(IV) complexes can effectively enhance the Pt cellular uptake and DNA platination. Results suggested glucose-conjugated Pt(IV) complexes had potential for further study as new anticancer agents.

Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance

Quinone oxidoreductase isozyme I (NQO1) is a cytoprotective two-electron-specific reductase that highly expresses in various cancer cells. Taking NQO1 as the target, we herein report three hybrid compounds from Pt(IV) complexes and a quinone propionic acid unit. The mechanism studies showed that the hybrids could be activated by both NQO1 and ascorbic acid to release the cytotoxic Pt(II) unit, exhibiting a dual stimuli-responsive character. In the pharmacological studies, complexes 2 and 3 presented higher antitumor activity than cisplatin. More importantly, the hybrid could also overcome cisplatin resistance due to the NQO1 targeting ability, improved cellular uptake, and/or different action mechanism. Significantly, complex 3 containing a coumarin moiety could be effectively activated in NQO1-overexpressed cancer cells to "turn on" fluorescence, showing a promising visual effect in cancer cells. In vivo study revealed that both 2 and 3 exhibited higher antitumor efficacy than cisplatin in the A549 xenograft mouse model at an equimolar dose to cisplatin. In all, the hybrids may serve as promising NQO1-targeting anticancer agents.

A highly efficient and selective antitumor agent based on a glucoconjugated carbene platinum(ii) complex

A Pt(ii) complex with a glucosylated carbene shows very high in vitro cytotoxicity and selectivity toward malignant cells.